Brand Name:
Sust M ‘250’
10mL/Vial
(Testosterone Propionate)
(Testosterone Phenylpropionate)
(Testosterone Isocaproate)
(Testosterone Decanoate)
Manufactured By:
Munster Laboratories Switzerland
Composition:
Each ml of the oily solution contains:
testosterone propionate (Eur. P.)………… 30 mg
testosterone phenylpropionate (B.P.)……. 60 mg
testosterone isocaproate (B.P.)…………... 60 mg
testosterone decanoate (B.P.)……………100 mg
Characteristics:
Sust M ‘250’ is an androgenic preparation for intramuscular administration containing four different esters of the natural hormone testosterone. Testosterone propionate has a rapid onset and a short duration of action. Testosterone phenylpropionate and isocaproate have a less rapid onset and a long duration of action. By combining these testosterone esters, the action of Sustanon ‘250’ starts shortly after injection and is maintained for about three weeks.
Sust M ‘250’ is generally well tolerated and has no adverse effect on the liver.
Indications:
Testosterone replacement therapy in male hypogonadal disorders, for example:
- after castration
- eunuchoidism
- hypopituitarism
- endocrine impotence
- male climacteric symptoms such as decreased libido and decreased mental and physical activity
- certain types of infertility due to disorders of spermatogenesis;
Moreover, testosterone therapy may be indicated in osteoporosis due to androgen deficiency.
Dosage:
In general, dosage should be adjusted according to the response of the individual patient. Usually, one injection of 1 ml per three weeks is adequate or as prescribed by the physician.
Administration:
Sust M ‘250’ should be administered by deep intramuscular injection.
Contra-indications:
- Known or suspected prostatic or mammary carcinoma.
Warnings and precautions:
- If androgen associated adverse reactions occur, treatment should be interrupted and after disappearance of the symptoms, should be resumed at a lower dosage.
- Patients with latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions) should be monitored, since androgens may occasionally induce salt and fluid retention.
- Androgens should be used cautiously in prepubertal boys to avoid premature epiphyseal closure or precocious sexual development.
- Oligosperma and decreased ejaculatory volume.
- A decrease in protein-bound iodine (PBI) may occur, but this has no clinical significance.
Adverse reactions:
The following adverse reactions have been associated with androgen therapy:
- Priapism and other signs of excessive sexual stimulation.
- In prepubertal boys, precocious sexual development, an increased frequency of erections, phallic enlargement and premature epiphyseal closure.
- Water and salt retention.
- Oligosperma and decreased ejaculatory volume.
Instructions:
To be sold on the prescription of a registered medical practitioner only.
Store at 8-30°C. Protect from light.
Keep out of the reach of children.